Literature DB >> 8765114

Cyclizine abuse by teenagers in Utah.

K E Bassett1, J E Schunk, B I Crouch.   

Abstract

Substance abuse by teenagers is common, often involving use of alcohol and illicit drugs. Ingestion of cyclizine hydrochloride, a nonprescription medication, was noted to occur frequently in Utah for abuse reasons. A retrospective review was conducted of patients younger than 18 years of age over a 3-year period who intentionally ingested cyclizine identified from Utah Poison Control Center records. Eighty patients were included; 42 patients underwent hospital record review. Abuse accounted for 89% of cyclizine ingestions; hallucinations (70%) and confusion/disorientation (40%) were the most notable symptoms. Tachycardia (52%) and systolic hypertension (69%) were frequently present in patients who presented to a hospital. No serious complications occurred. This study illustrates teenage abuse of one nonprescription antihistamine presumably to induce hallucinations. Abuse of over-the-counter medications by adolescents may be more appealing than illicit drug use for numerous reasons, and may be more common than appreciated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8765114     DOI: 10.1016/S0735-6757(96)90156-4

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  3 in total

1.  Abuse/misuse of non-prescription drugs.

Authors:  G F Hughes; J C McElnay; C M Hughes; P McKenna
Journal:  Pharm World Sci       Date:  1999-12

2.  Development of a community pharmacy-based model to identify and treat OTC drug abuse/misuse: a pilot study.

Authors:  Glenda F Fleming; James C McElnay; Carmel M Hughes
Journal:  Pharm World Sci       Date:  2004-10

3.  Spectrofluorimetric Approach for Quantification of Cyclizine in the Presence of its Toxic Impurities in Human Plasma; in silico Study and ADMET Calculations.

Authors:  Michel Y Fares; Nada S Abdelwahab; Ghada M El-Sayed; Maha A Hegazy; Maha M Abdelrahman
Journal:  J Fluoresc       Date:  2022-03-03       Impact factor: 2.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.